Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Non-Current Deffered Revenue (2019 - 2025)

Silence Therapeutics (SLN) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $55.5 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue rose 7.07% to $55.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $55.5 million through Dec 2025, up 7.07% year-over-year, with the annual reading at $55.5 million for FY2025, 7.07% up from the prior year.
  • Non-Current Deffered Revenue hit $55.5 million in Q4 2025 for Silence Therapeutics, roughly flat from $55.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $97.7 million in Q4 2021 to a low of $51.8 million in Q4 2024.
  • Historically, Non-Current Deffered Revenue has averaged $64.7 million across 5 years, with a median of $55.9 million in 2025.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 44.17% in 2021 and later fell 29.17% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $97.7 million in 2021, then fell by 23.81% to $74.5 million in 2022, then decreased by 1.81% to $73.1 million in 2023, then dropped by 29.17% to $51.8 million in 2024, then grew by 7.07% to $55.5 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for SLN at $55.5 million in Q4 2025, $55.3 million in Q3 2025, and $56.3 million in Q2 2025.